Further analysis of tumor tissues, confirmed the in vitro results that when compared to the vehicle-treated group, SF + MU treatment downregulated phospho-MET, and CD44 levels in EV tumors, but not in A9 tumors (Fig. 6b). The gene discussed is MET; the disease is neoplasm.